Short Interest in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Increases By 41.3%

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) was the recipient of a large increase in short interest in August. As of August 15th, there was short interest totalling 474,600 shares, an increase of 41.3% from the July 31st total of 336,000 shares. Approximately 5.9% of the shares of the stock are sold short. Based on an average daily volume of 90,000 shares, the days-to-cover ratio is presently 5.3 days.

Institutional Trading of NRx Pharmaceuticals

An institutional investor recently bought a new position in NRx Pharmaceuticals stock. AdvisorShares Investments LLC acquired a new position in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 642,632 shares of the company’s stock, valued at approximately $296,000. AdvisorShares Investments LLC owned approximately 0.75% of NRx Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 4.27% of the stock is owned by institutional investors and hedge funds.

NRx Pharmaceuticals Stock Performance

Shares of NRXP stock traded down $0.05 during mid-day trading on Thursday, hitting $1.83. The company’s stock had a trading volume of 43,138 shares, compared to its average volume of 223,344. The company’s fifty day simple moving average is $2.25 and its 200-day simple moving average is $14.61. The company has a market cap of $19.58 million, a PE ratio of -0.59 and a beta of 1.26. NRx Pharmaceuticals has a 52 week low of $1.68 and a 52 week high of $7.33.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.75) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.06. On average, equities analysts anticipate that NRx Pharmaceuticals will post -4 earnings per share for the current year.

Wall Street Analyst Weigh In

NRXP has been the subject of a number of research reports. Ascendiant Capital Markets dropped their price target on NRx Pharmaceuticals from $50.00 to $43.00 and set a “buy” rating for the company in a research note on Friday, June 7th. HC Wainwright raised their target price on NRx Pharmaceuticals from $2.00 to $19.00 and gave the stock a “buy” rating in a research report on Monday, August 5th.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.